Lonza wins biopharma contract from UCB
Lonza has won a major new contract for its biopharmaceutical manufacturing facility in Visp, Switzerland, making bulk actives for Belgian company UCB, reports Phil Taylor.
Lonza has won a major new contract for its biopharmaceutical manufacturing facility in Visp, Switzerland, making bulk actives for Belgian company UCB, reports Phil Taylor.
Researchers may have found a novel way to fight asthma by targeting a protein that is centrally involved in the bronchial inflammation and airway constriction that prompts asthma's hallmark symptoms. The antibody treatment is one of a new class of...
The discovery of a new batch of counterfeit drugs circulating in the US market adds urgency to ongoing efforts to improve traceability in the medicines supply chain, and will also lend weight to arguments against parallel trade in pharmaceuticals,...
Eksigent Technologies introduces a new range of software drivers and hardware accessories that ensure sample delivery at a pace that improves the throughput of its eight-channel HPLC system.
Japanese packaging machinery firm Shibuya Kogyo is close to finalising its acquisition of Hoppmann, a move that will expand the firm's presence within the lucrative US market.
US firm Codexis and Shasun Chemicals and Drugs of India have signed a manufacturing and supply agreement for a pharmaceutical intermediate for a generic drug.
DSM is to close down production of bulk vitamin C in the US and cut costs at its plant in Dalry, Scotland, as part of a series of measures to ease pressure on its vitamin business, reports Dominique Patton.